|
Re: No love
|
5
|
Resverlogix Corp.
|
Dec 13, 2018 12:32PM
|
|
Re: The positive view
|
5
|
Resverlogix Corp.
|
Oct 13, 2017 01:11PM
|
|
Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
5
|
Zenith Epigenetics
|
Sep 02, 2018 12:14PM
|
|
Re: New Deal premium to market ...
|
5
|
Resverlogix Corp.
|
Mar 25, 2016 12:26PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
5
|
Resverlogix Corp.
|
May 11, 2017 08:01AM
|
|
Japanese publication response from IR
|
5
|
Zenith Epigenetics
|
Nov 01, 2016 08:32AM
|
|
Re: Pre IPO?!!
|
5
|
Zenith Epigenetics
|
Dec 13, 2017 03:30PM
|
|
Re: Where are we heading here?
|
5
|
Resverlogix Corp.
|
Aug 02, 2018 04:25PM
|
|
Pfizer new focus for future $5 Billion in Annual sales
|
5
|
Zenith Epigenetics
|
Jan 06, 2019 11:46AM
|
|
Re: Zenith Private placement??
|
5
|
Zenith Epigenetics
|
Feb 21, 2018 10:26AM
|
|
Re: Lu stepping down
|
5
|
Resverlogix Corp.
|
Feb 21, 2024 07:19PM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
5
|
Zenith Epigenetics
|
Feb 11, 2022 12:21PM
|
|
Angiotensin and Coronavirus
|
5
|
Resverlogix Corp.
|
Mar 23, 2020 05:49PM
|
|
Re: AGM & PP
|
5
|
Resverlogix Corp.
|
Nov 23, 2020 12:38PM
|
|
Re: Dr Johann
|
5
|
Resverlogix Corp.
|
Apr 05, 2016 03:41PM
|
|
Re: Additional Exempt Distribution
|
5
|
Zenith Epigenetics
|
Dec 06, 2023 11:28AM
|
|
Re: Gilead's GS-5829 flops in mCRPC
|
5
|
Zenith Epigenetics
|
Jul 13, 2022 12:40PM
|
|
Re: Statistical Considerations
|
5
|
Resverlogix Corp.
|
Mar 09, 2018 08:26AM
|
|
RVX warrant exercise incentive program
|
5
|
Resverlogix Corp.
|
Dec 02, 2019 02:42PM
|
|
Zenith or Rvx in play...
|
5
|
Resverlogix Corp.
|
Oct 02, 2016 12:59PM
|
